title: Inactivation of the bed nucleus of the stria terminalis in an animal model of relapse: effects on conditioned cue-induced reinstatement and its enhancement by yohimbine.
abstract: BACKGROUND
  Drug-associated cues and stress increase craving and lead to greater risk of relapse in abstinent drug users. Animal models of reinstatement of drug seeking have been utilized to study the neural circuitry by which either drug-associated cues or stress exposure elicit drug seeking. Recent evidence has shown a strong enhancing effect of yohimbine stress on subsequent cue-elicited reinstatement; however, there has been no examination of the neural substrates of this interactive effect.
  
  
  OBJECTIVE
  The current study examined whether inactivation of the bed nucleus of the stria terminalis (BNST), an area previously implicated in stress activation of drug seeking, would affect reinstatement of cocaine seeking caused by conditioned cues, yohimbine stress, or the combination of these factors.
  
  
  METHODS
  Male rats experienced daily IV cocaine self-administration, followed by extinction of lever responding in the absence of cocaine-paired cues. Reinstatement of responding was measured during presentation of cocaine-paired cues, following pretreatment with the pharmacological stressor, yohimbine (2.5 mg/kg, IP), or the combination of cues and yohimbine.
  
  
  RESULTS
  All three conditions led to reinstatement of cocaine seeking, with the highest responding seen after the combination of cues and yohimbine. Reversible inactivation of the BNST using the gamma-aminobutyric acid receptor agonists, baclofen + muscimol, significantly reduced all three forms of reinstatement.
  
  
  CONCLUSIONS
  These results demonstrate a role for the BNST in cocaine seeking elicited by cocaine-paired cues, and suggest the BNST as a key mediator for the interaction of stress and cues for the reinstatement of cocaine seeking.
authors.affiliation: Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.
authors.forename: Deanne M
authors.initials: DM
authors.lastname: Buffalari
authors.forename: Ronald E
authors.initials: RE
authors.lastname: See
mesh_terms: D000818:Animals; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003042:Cocaine / Q000008:administration & dosage / Q000494:pharmacology; D019970:Cocaine-Related Disorders / Q000503:physiopathology* / Q000517:prevention & control*; D003216:Conditioning, Operant / Q000187:drug effects*; D003463:Cues; D004359:Drug Therapy, Combination; D005108:Extinction, Psychological / Q000187:drug effects*; D008297:Male; D023421:Models, Animal; D009118:Muscimol / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D055502:Secondary Prevention; D012646:Self Administration / Q000379:methods; D012686:Septal Nuclei / Q000187:drug effects / Q000502:physiology*; D015016:Yohimbine / Q000494:pharmacology*
chemical_list: D009118:Muscimol; D015016:Yohimbine; D001418:Baclofen; D003042:Cocaine
references.citation: Neuroscience. 2006;138(1):235-43
references.pmid: 16359808
references.citation: Synapse. 2000 Feb;35(2):79-95
references.pmid: 10611634
references.citation: Neurobiol Learn Mem. 1996 Nov;66(3):253-7
references.pmid: 8946419
references.citation: J Neurosci. 2001 Aug 15;21(16):RC160
references.pmid: 11473131
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1336-46
references.pmid: 19616054
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):21-30
references.pmid: 12695875
references.citation: Ann N Y Acad Sci. 2003 Apr;985:185-205
references.pmid: 12724159
references.citation: Psychopharmacology (Berl). 2004 Nov;176(3-4):459-65
references.pmid: 15138757
references.citation: Psychopharmacology (Berl). 2005 May;179(2):366-73
references.pmid: 15551068
references.citation: NIDA Res Monogr. 1993;137:73-95
references.pmid: 8289929
references.citation: Biol Psychiatry. 2007 Mar 1;61(5):582-90
references.pmid: 16806092
references.citation: Nature. 2000 Jan 27;403(6768):430-4
references.pmid: 10667795
references.citation: Peptides. 1984;5 Suppl 1:227-39
references.pmid: 6384952
references.citation: Neuropsychopharmacology. 2003 Jan;28(1):73-6
references.pmid: 12496942
references.citation: Psychopharmacology (Berl). 1997 Aug;132(3):289-95
references.pmid: 9292629
references.citation: Psychopharmacology (Berl). 2006 Jul;187(1):60-7
references.pmid: 16598453
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):66-74
references.pmid: 12442201
references.citation: J Neurosci. 2008 Dec 17;28(51):13856-65
references.pmid: 19091975
references.citation: Psychopharmacology (Berl). 2000 Jun;150(3):337-46
references.pmid: 10923762
references.citation: J Neurosci. 1999 Oct 15;19(20):RC35
references.pmid: 10516337
references.citation: Pharmacol Biochem Behav. 2002 Mar;71(3):517-29
references.pmid: 11830186
references.citation: Psychopharmacology (Berl). 1996 Dec;128(4):408-12
references.pmid: 8986011
references.citation: Psychopharmacology (Berl). 2009 Mar;203(1):121-30
references.pmid: 18985323
references.citation: Brain Res. 1999 May 1;826(2):243-52
references.pmid: 10224302
references.citation: Br J Pharmacol. 2008 May;154(2):261-74
references.pmid: 18311189
references.citation: Pharmacol Biochem Behav. 2010 Jul;96(1):24-31
references.pmid: 20394767
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1289-90
references.pmid: 19602427
references.citation: Pharmacol Biochem Behav. 2008 Apr;89(2):227-33
references.pmid: 18230406
references.citation: Neuroscience. 2009 Nov 10;163(4):1069-77
references.pmid: 19589368
references.citation: Eur Neuropsychopharmacol. 2003 Dec;13(6):442-52
references.pmid: 14636960
references.citation: Behav Brain Res. 1997 Sep;87(2):139-48
references.pmid: 9331482
references.citation: Neuropsychopharmacology. 2004 Apr;29(4):686-93
references.pmid: 14872205
references.citation: J Neurosci Methods. 1980 Dec;3(2):129-49
references.pmid: 6110810
references.citation: Psychopharmacology (Berl). 2009 Jun;204(3):445-55
references.pmid: 19266185
references.citation: Psychopharmacology (Berl). 1999 Mar;142(4):343-51
references.pmid: 10229058
references.citation: J Neurosci. 2006 Nov 1;26(44):11442-53
references.pmid: 17079674
references.citation: Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
references.pmid: 10967352
references.citation: J Neurosci. 2001 Nov 1;21(21):8655-63
references.pmid: 11606653
references.citation: Behav Brain Res. 2010 Mar 17;208(1):144-8
references.pmid: 19931573
references.citation: Biol Psychiatry. 2002 Apr 15;51(8):642-51
references.pmid: 11955464
references.citation: J Neurosci. 2004 Jul 21;24(29):6600-10
references.pmid: 15269272
references.citation: Psychopharmacology (Berl). 1981;75(2):134-43
references.pmid: 6798603
references.citation: Biol Psychiatry. 2004 Jun 1;55(11):1082-9
references.pmid: 15158427
references.citation: Ann N Y Acad Sci. 1999 Jun 29;877:486-98
references.pmid: 10415666
references.citation: J Neurosci Res. 1997 Dec 15;50(6):1040-6
references.pmid: 9452019
references.citation: Biol Psychiatry. 1999 Nov 1;46(9):1192-204
references.pmid: 10560025
references.citation: J Neurosci. 2002 Jul 1;22(13):5713-8
references.pmid: 12097523
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):583-7
references.pmid: 3412496
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):57-65
references.pmid: 12845418
references.citation: Behav Brain Res. 2006 Nov 1;174(1):1-8
references.pmid: 16920204
references.citation: Neuropsychopharmacology. 2005 Apr;30(4):657-68
references.pmid: 15602500
references.citation: Eur J Pharmacol. 2005 Dec 5;526(1-3):140-6
references.pmid: 16253228
references.citation: J Pharmacol Exp Ther. 1980 Nov;215(2):494-9
references.pmid: 7192314
references.citation: J Neurosci. 2002 Jun 15;22(12):5173-87
references.pmid: 12077212
references.citation: J Neurochem. 2004 Nov;91(3):683-93
references.pmid: 15485498
references.citation: Neuroscience. 2008 Jan 24;151(2):579-88
references.pmid: 18061358
references.citation: Am J Psychiatry. 1987 Aug;144(8):1030-6
references.pmid: 3037926
references.citation: Nat Rev Neurosci. 2007 Nov;8(11):844-58
references.pmid: 17948030
references.citation: Nat Neurosci. 2005 Apr;8(4):413-4
references.pmid: 15735642
references.citation: Int J Neuropsychopharmacol. 2009 Apr;12(3):431-6
references.pmid: 19236732
references.citation: Arch Gen Psychiatry. 2006 Mar;63(3):324-31
references.pmid: 16520439
references.citation: Pharmacol Biochem Behav. 1989 Jan;32(1):151-6
references.pmid: 2567522
references.citation: Physiol Behav. 2009 Dec 7;98(5):614-7
references.pmid: 19800355
references.citation: Curr Psychiatry Rep. 2007 Oct;9(5):374-80
references.pmid: 17915076
references.citation: J Neurosci. 2000 Oct 15;20(20):RC102
references.pmid: 11027253
references.citation: Brain Struct Funct. 2008 Sep;213(1-2):43-61
references.pmid: 18651175
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81
references.pmid: 11172061
references.citation: Behav Brain Res. 1986 Sep;21(3):189-94
references.pmid: 2876714
references.citation: J Neurosci. 2009 Apr 29;29(17):5389-401
references.pmid: 19403807
references.citation: J Neurosci. 2004 Feb 18;24(7):1551-60
references.pmid: 14973230